440 related articles for article (PubMed ID: 31652993)
1. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
Shevtsov M; Multhoff G; Mikhaylova E; Shibata A; Guzhova I; Margulis B
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652993
[TBL] [Abstract][Full Text] [Related]
2. [Thermosensitization of tumor cells with inhibitors of chaperone activity and expression].
Kudriavtsev VA; Makarova IuM; Kabakav AE
Biomed Khim; 2012; 58(6):662-72. PubMed ID: 23350198
[TBL] [Abstract][Full Text] [Related]
3. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review).
Wang X; Chen M; Zhou J; Zhang X
Int J Oncol; 2014 Jul; 45(1):18-30. PubMed ID: 24789222
[TBL] [Abstract][Full Text] [Related]
4. Targeting heat shock proteins in cancer.
Jego G; Hazoumé A; Seigneuric R; Garrido C
Cancer Lett; 2013 May; 332(2):275-85. PubMed ID: 21078542
[TBL] [Abstract][Full Text] [Related]
5. Re-examining HSPC1 inhibitors.
Lee SL; Dempsey-Hibbert NC; Vimalachandran D; Wardle TD; Sutton PA; Williams JH
Cell Stress Chaperones; 2017 Mar; 22(2):293-306. PubMed ID: 28255900
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents.
Nitzsche B; Höpfner M; Biersack B
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835501
[TBL] [Abstract][Full Text] [Related]
7. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?
Powers MV; Jones K; Barillari C; Westwood I; van Montfort RL; Workman P
Cell Cycle; 2010 Apr; 9(8):1542-50. PubMed ID: 20372081
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein antagonists in early stage clinical trials for NSCLC.
Hendriks LEL; Dingemans AC
Expert Opin Investig Drugs; 2017 May; 26(5):541-550. PubMed ID: 28274158
[TBL] [Abstract][Full Text] [Related]
9. Modulatory effects of curcumin on heat shock proteins in cancer: A promising therapeutic approach.
Forouzanfar F; Barreto G; Majeed M; Sahebkar A
Biofactors; 2019 Sep; 45(5):631-640. PubMed ID: 31136038
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HSP70: a challenging anti-cancer strategy.
Goloudina AR; Demidov ON; Garrido C
Cancer Lett; 2012 Dec; 325(2):117-24. PubMed ID: 22750096
[TBL] [Abstract][Full Text] [Related]
11. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties.
Garrido C; Brunet M; Didelot C; Zermati Y; Schmitt E; Kroemer G
Cell Cycle; 2006 Nov; 5(22):2592-601. PubMed ID: 17106261
[TBL] [Abstract][Full Text] [Related]
12. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
13. Heat shock proteins in multiple myeloma.
Zhang L; Fok JH; Davies FE
Oncotarget; 2014 Mar; 5(5):1132-48. PubMed ID: 24675290
[TBL] [Abstract][Full Text] [Related]
14. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
15. C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances.
Muller P; Ruckova E; Halada P; Coates PJ; Hrstka R; Lane DP; Vojtesek B
Oncogene; 2013 Jun; 32(25):3101-10. PubMed ID: 22824801
[TBL] [Abstract][Full Text] [Related]
16. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
Ischia J; Saad F; Gleave M
Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the Hsp90 cochaperone cyclophilin 40 with Hsc70.
Carrello A; Allan RK; Morgan SL; Owen BA; Mok D; Ward BK; Minchin RF; Toft DO; Ratajczak T
Cell Stress Chaperones; 2004; 9(2):167-81. PubMed ID: 15497503
[TBL] [Abstract][Full Text] [Related]
18. [Heat shock proteins: new target in cytoprotective and tumor therapy].
Bao XQ; Liu GT
Yao Xue Xue Bao; 2008 Mar; 43(3):234-40. PubMed ID: 18630257
[TBL] [Abstract][Full Text] [Related]
19. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.
Yeramian A; Vea A; Benítez S; Ribera J; Domingo M; Santacana M; Martinez M; Maiques O; Valls J; Dolcet X; Vilella R; Cabiscol E; Matias-Guiu X; Marti RM
Pigment Cell Melanoma Res; 2016 May; 29(3):352-71. PubMed ID: 26988132
[TBL] [Abstract][Full Text] [Related]
20. Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70.
Wang Y; McAlpine SR
Org Biomol Chem; 2015 Feb; 13(7):2108-16. PubMed ID: 25526223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
